

DAFTAR PUSTAKA

- Abushaheen, M. A. *et al.* (2020) 'Antimicrobial resistance, mechanisms and its clinical significance', *Disease-a-Month*. Elsevier Inc., 66(6). doi: 10.1016/j.disamonth.2020.100971.
- Alali, M., David, M. Z., Danziger-Isakov, L. A., Bartlett, A. H., *et al.* (2020) 'Association Between Depth of Neutropenia and Clinical Outcomes in Febrile Pediatric Cancer and/or Patients Undergoing Hematopoietic Stem-cell Transplantation', *Pediatric Infectious Disease Journal*, 39(7), pp. 628–633. doi: 10.1097/INF.0000000000002641.
- Alali, M., David, M. Z., Danziger-Isakov, L. A., Elmuti, L., *et al.* (2020) 'Pediatric febrile neutropenia: Change in etiology of bacteremia, empiric choice of therapy and clinical outcomes', *Journal of Pediatric Hematology/Oncology*, 42(6), pp. E445–E451. doi: 10.1097/MPH.0000000000001814.
- Alali, M. *et al.* (2022) 'A prediction model for bacteremia and transfer to intensive care in pediatric and adolescent cancer patients with febrile neutropenia', *Scientific Reports*. Nature Publishing Group UK, 12(1), pp. 1–10. doi: 10.1038/s41598-022-11576-z.
- Anderson, K. *et al.* (2020) 'Addressing the barriers to optimal management of febrile neutropenia in children with cancer', *European Journal of Oncology Nursing*. Elsevier, 45(October 2019), p. 101719. doi: 10.1016/j.ejon.2019.101719.
- Avilés-Robles, M. J. *et al.* (2020) 'Safety and efficacy of step-down to oral outpatient treatment versus inpatient antimicrobial treatment in pediatric cancer patients with febrile neutropenia: A noninferiority multicenter randomized clinical trial', *Pediatric Blood and Cancer*, 67(6), pp. 1–7. doi: 10.1002/pbc.28251.
- Ayukekbong, J. A., Ntemgwa, M. and Atabe, A. N. (2017) 'The threat of antimicrobial resistance in developing countries: Causes and control strategies', *Antimicrobial Resistance and Infection Control*. Antimicrobial Resistance & Infection Control, 6(1), pp. 1–8. doi: 10.1186/s13756-017-0208-x.
- Baraka, A. and Zakaria, M. (2018) 'Procalcitonin as a diagnostic marker of bacterial infections in febrile neutropenic pediatric patients with hematological malignancies', *International Journal of Hematology*. Springer Japan, 108(2), pp. 184–191. doi: 10.1007/s12185-018-2447-x.
- Barber, M. D., Ross, J. A. and Fearon, K. C. H. (1999) 'Cancer cachexia', *Surgical Oncology*, 8(3), pp. 133–141. doi: 10.1016/S0960-7404(99)00045-6.
- Boccia, R. *et al.* (2022) 'Chemotherapy-Induced Neutropenia and Febrile Neutropenia in the US: A Beast of Burden That Needs to Be Tamed?', *The oncologist*, 27(8), pp. 625–636. doi: 10.1093/oncolo/oyac074.
- Boeriu, E. *et al.* (2022) 'Diagnosis and Management of Febrile Neutropenia in Pediatric Oncology Patients—A Systematic Review', *Diagnostics*, 12(8), pp. 1–12. doi: 10.3390/diagnostics12081800.
- Bossù, G. *et al.* (2021) 'Antimicrobial prophylaxis and modifications of the gut

- microbiota in children with cancer', *Antibiotics*, 10(2), pp. 1–15. doi: 10.3390/antibiotics10020152.
- Burns, B. *et al.* (2019) 'Optimizing Time to Antibiotic Administration in Children with Possible Febrile Neutropenia through Quality Improvement Methodologies', *Pediatric Quality & Safety*, 4(6), p. e236. doi: 10.1097/pq9.0000000000000236.
- Campion, M. and Scully, G. (2018) 'Antibiotic Use in the Intensive Care Unit: Optimization and De-Escalation', *Journal of Intensive Care Medicine*, 33(12), pp. 647–655. doi: 10.1177/0885066618762747.
- Cennamo, F. *et al.* (2021) 'Update on febrile neutropenia in pediatric oncological patients undergoing chemotherapy', *Children*, 8(12), pp. 1–9. doi: 10.3390/children8121086.
- Cunha, C. B. and Opal, S. M. (2018) 'Antibiotic Stewardship: Strategies to Minimize Antibiotic Resistance While Maximizing Antibiotic Effectiveness', *Medical Clinics of North America*. Elsevier Inc, 102(5), pp. 831–843. doi: 10.1016/j.mcna.2018.04.006.
- Van Cutsem, E. and Arends, J. (2005) 'The causes and consequences of cancer-associated malnutrition', *European Journal of Oncology Nursing*, 9(SUPPL. 2). doi: 10.1016/j.ejon.2005.09.007.
- Dale, D. C. *et al.* (2022) 'Outcomes for patients with severe chronic neutropenia treated with granulocyte colony-stimulating factor', *Blood Advances*, 6(13), pp. 3861–3869. doi: 10.1182/bloodadvances.2021005684.
- Doerflinger, M. *et al.* (2021) 'Procalcitonin and Interleukin-10 May Assist in Early Prediction of Bacteraemia in Children With Cancer and Febrile Neutropenia', *Frontiers in Immunology*, 12(May), pp. 1–9. doi: 10.3389/fimmu.2021.641879.
- Evans, S. E. and Ost, D. E. (2015) 'Pneumonia in the neutropenic cancer patient', *Current Opinion in Pulmonary Medicine*, 21(3), pp. 260–271. doi: 10.1097/MCP.0000000000000156.
- El Feghaly, R. E. *et al.* (2018) 'A quality improvement initiative: Reducing blood culture contamination in a children's hospital', *Pediatrics*, 142(4). doi: 10.1542/peds.2018-0244.
- Fehér, C. *et al.* (2014) 'Effect of meropenem administration in extended infusion on the clinical outcome of febrile neutropenia: A retrospective observational study', *Journal of Antimicrobial Chemotherapy*, 69(9), pp. 2556–2562. doi: 10.1093/jac/dku150.
- Hansen, B. A. *et al.* (2020) 'Febrile neutropenia in acute leukemia. Epidemiology, etiology, pathophysiology and treatment', *Mediterranean Journal of Hematology and Infectious Diseases*, 11(1), pp. 1–19. doi: 10.4084/MJHID.2020.009.
- Hanzelina, H. *et al.* (2022) 'Malnutrition as Risk Factor for Febrile Neutropenia in Children with Acute Lymphoblastic Leukemia', *Open Access Macedonian Journal of Medical Sciences*, 10(B), pp. 681–685. doi: 10.3889/oamjms.2022.8448.
- Huemer, M. *et al.* (2020) 'Antibiotic resistance and persistence—Implications for human health and treatment perspectives', *EMBO reports*, 21(12), pp. 1–24.

doi: 10.15252/embr.202051034.

- Israels, T. *et al.* (2021) 'Fever and neutropenia outcomes and areas for intervention: A report from SUCCOUR - Supportive Care for Children with Cancer in Africa', *Pediatric Blood and Cancer*, 68(9), pp. 1–6. doi: 10.1002/pbc.29224.
- Kanvinde, S. *et al.* (2022) 'Once-a-Day Ceftriaxone-Amikacin Combination as Empiric Antibiotic Therapy to Enable Outpatient Management of Febrile Neutropenia in Children-16-Year Experience from a Single Institute', *South Asian Journal of Cancer*, 11(4), pp. 370–377. doi: 10.1055/s-0042-1745834.
- Kapoor, R. *et al.* (2018) 'Clinicohematological profile of febrile neutropenia in childhood acute leukemia and utility of serum procalcitonin levels in neutropenic patients', *Indian Journal of Critical Care Medicine*, 22(5), pp. 336–339. doi: 10.4103/ijccm.IJCCM_516_17.
- Kara, S. S. *et al.* (2019) 'Risk factors for bacteremia in children with febrile neutropenia', *Turkish Journal of Medical Sciences*, 49(4), pp. 1198–1205. doi: 10.3906/sag-1901-90.
- Kaya, Z. *et al.* (2023) 'Identifying Risk Factors and Improving Preventive Strategies for Febrile Neutropenia in Children with Leukemia Receiving Ciprofloxacin Prophylaxis', *Turkish Journal of Hematology*, pp. 0–0. doi: 10.4274/tjh.galenos.2023.2023-0116.
- Klastersky, J. *et al.* (2016) 'Management of febrile neutropaenia: ESMO clinical practice guidelines', *Annals of Oncology*, 27(August), pp. v111–v118. doi: 10.1093/annonc/mdw325.
- Kumar, J. *et al.* (2018) 'Prevalence and Predictors of Invasive Fungal Infections in Children with Persistent Febrile Neutropenia Treated for Acute Leukemia – A Prospective Study', *Indian Journal of Pediatrics*. The Indian Journal of Pediatrics. doi: 10.1007/s12098-018-2722-0.
- Kuti, J. L. (2016) 'Optimizing Antimicrobial Pharmacodynamics: a Guide for Your Stewardship Program', *Revista Médica Clínica Las Condes*, 27(5), pp. 615–624. doi: 10.1016/j.rmcl.2016.08.001.
- de la Court, J. R. *et al.* (2022) 'The Dutch Working Party on Antibiotic Policy (SWAB) Recommendations for the Diagnosis and Management of Febrile Neutropenia in Patients with Cancer', *Infectious Diseases and Therapy*. Springer Healthcare, 11(6), pp. 2063–2098. doi: 10.1007/s40121-022-00700-1.
- Lech-Maranda, E. *et al.* (2010) 'Infectious complications in patients with acute myeloid leukemia treated according to the protocol with daunorubicin and cytarabine with or without addition of cladribine. A multicenter study by the Polish Adult Leukemia Group (PALG)', *International Journal of Infectious Diseases*. International Society for Infectious Diseases, 14(2), pp. e132–e140. doi: 10.1016/j.ijid.2009.02.021.
- Lehrnbecher, T. *et al.* (2021) '8th European Conference on Infections in Leukaemia: 2020 guidelines for the use of antibiotics in paediatric patients with cancer or post-haematopoietic cell transplantation', *The Lancet Oncology*. Elsevier Ltd, 22(6), pp. e270–e280. doi: 10.1016/S1470-2045(20)30725-7.
- Lekshminarayanan, A. *et al.* (2018) 'National Trends in Hospitalization for Fever and Neutropenia in Children with Cancer, 2007-2014', *Journal of Pediatrics*.

- Elsevier Inc., 202, pp. 231–237.e3. doi: 10.1016/j.jpeds.2018.06.056.
- Levene, I., Castagnola, E. and Haeusler, G. M. (2018) ‘Antibiotic-resistant Gram-negative Blood Stream Infections in Children with Cancer: A Review of Epidemiology, Risk Factors, and Outcome’, *Pediatric Infectious Disease Journal*, 37(5), pp. 495–498. doi: 10.1097/INF.0000000000001938.
- Lösemlil, A. *et al.* (2023) ‘Etiology and Factors Affecting Severe Complications and Mortality of Febrile Neutropenia in Children with Acute Leukemia’, pp. 143–153. doi: 10.4274/tjh.galenos.2023.2023.0185.
- Mahar, U. *et al.* (2020) ‘Emerging anti-microbial resistance in febrile neutropenia: Is it high time to evaluate quality control measures?’, *Pakistan Journal of Medical Sciences*, 36(6), pp. 1–6. doi: 10.12669/pjms.36.6.2138.
- McInnes, R. S. *et al.* (2020) ‘Horizontal transfer of antibiotic resistance genes in the human gut microbiome’, *Current Opinion in Microbiology*. Elsevier Ltd, 53, pp. 35–43. doi: 10.1016/j.mib.2020.02.002.
- Meena, J. P., Gupta, A. K. and Seth, R. (2020) ‘Outcomes of Febrile Neutropenia in Children with Cancer Managed on an Outpatient Basis: A Report from Tertiary Care Hospital from a Resource-limited Setting’, *Journal of Pediatric Hematology/Oncology*, 42(8), pp. 467–473. doi: 10.1097/MPH.0000000000001896.
- Meng, H. *et al.* (2022) ‘Risk Factors for Mortality and Outcomes in Hematological Malignancy Patients with Carbapenem-Resistant *Klebsiella pneumoniae* Bloodstream Infections’, *Infection and Drug Resistance*, 15(August), pp. 4241–4251. doi: 10.2147/IDR.S374904.
- Mohammed, H. B. *et al.* (2019) ‘Febrile neutropenia management in pediatric cancer patients at Ethiopian Tertiary Care Teaching Hospital’, *BMC Research Notes*. BioMed Central, 12(1), pp. 1–6. doi: 10.1186/s13104-019-4569-5.
- Mongkolrattanothai, K. and Bard, J. D. (2019) ‘Sepsis in Children with Febrile Neutropenia’, *Journal of Applied Laboratory Medicine*, 3(4), pp. 530–533. doi: 10.1373/jalm.2018.028142.
- Morgan, J. E. *et al.* (2021) ‘Optimising antimicrobial selection and duration in the treatment of febrile neutropenia in children’, *Infection and Drug Resistance*, 14, pp. 1283–1293. doi: 10.2147/IDR.S238567.
- Naqvi, S. A. R. *et al.* (2018) ‘Ciprofloxacin: from infection therapy to molecular imaging’, *Molecular Biology Reports*. Springer Netherlands, 45(5), pp. 1457–1468. doi: 10.1007/s11033-018-4220-x.
- Nursyirwan, S. R. and Windiastuti, E. (2018) ‘Kejadian Demam Neutropenia pada Anak dengan Keganasan’, *Sari Pediatri*, 19(4), p. 220. doi: 10.14238/sp19.4.2017.220-25.
- Phillips, B. (2019) ‘Recent advances in the prevention and management of infections in children undergoing treatment for cancer [version 1; peer review: 2 approved]’, *F1000Research*, 8, pp. 6–11. doi: 10.12688/f1000research.19337.1.
- Raad, C. *et al.* (2021) ‘Trends in bacterial bloodstream infections and resistance in immuno-compromised patients with febrile neutropenia: a retrospective analysis’, *European Journal of Pediatrics*. European Journal of Pediatrics, 180(9), pp. 2921–2930. doi: 10.1007/s00431-021-04056-5.

- Reinecke, J. *et al.* (2019) 'Blood Stream Infections and Antibiotic Utilization in Pediatric Leukemia Patients with Febrile Neutropenia', *Journal of Pediatric Hematology/Oncology*, 41(4), pp. 251–255. doi: 10.1097/MPH.0000000000001279.
- Robinson, P. D. *et al.* (2016) 'Strategies for empiric management of pediatric fever and neutropenia in patients with cancer and hematopoietic stem-cell transplantation recipients: A systematic review of randomized trials', *Journal of Clinical Oncology*, 34(17), pp. 2054–2060. doi: 10.1200/JCO.2015.65.8591.
- Rondinelli, P. I. P., Ribeiro, K. D. C. B. and De Camargo, B. (2006) 'A proposed score for predicting severe infection complications in children with chemotherapy-induced febrile neutropenia', *Journal of Pediatric Hematology/Oncology*, 28(10), pp. 665–670. doi: 10.1097/01.mph.0000212996.94929.0b.
- Sano, H. *et al.* (2017) 'A prospective randomized trial comparing piperacillin/tazobactam with meropenem as empirical antibiotic treatment of febrile neutropenic children and adolescents with hematologic and malignant disorders', *Pediatric Blood and Cancer*, 64(6), pp. 1–5. doi: 10.1002/pbc.26360.
- Sano, H. *et al.* (2018) 'Differential efficacy of empirical antibiotic therapy for febrile neutropenia in adolescent/young adult (AYA) and child patients', *International Journal of Hematology*. Springer Japan, 108(5), pp. 543–549. doi: 10.1007/s12185-018-2503-6.
- Šegulja, S. *et al.* (2019) 'Simple predictors of the reoccurrence of severe febrile neutropenia episode: A singlecenter retrospective cohort study in pediatric patients with malignant diseases', *Croatian Medical Journal*, 60(1), pp. 20–25. doi: 10.3325/cmj.2019.60.20.
- Sieswerda, E. *et al.* (2022) 'The 2021 Dutch Working Party on Antibiotic Policy (SWAB) guidelines for empirical antibacterial therapy of sepsis in adults', *BMC Infectious Diseases*. BioMed Central, 22(1), pp. 1–16. doi: 10.1186/s12879-022-07653-3.
- Stern, A. *et al.* (2019) 'Early discontinuation of antibiotics for febrile neutropenia versus continuation until neutropenia resolution in people with cancer', *Cochrane Database of Systematic Reviews*, 2019(1). doi: 10.1002/14651858.CD012184.pub2.
- Sulviani, R., Idjradinata, P. and Raspati, H. (2007) 'Paediatrica Indonesiana', 47(2), pp. 83–87.
- Sureda, A., Domingo-Domenech, E. and Gautam, A. (2019) 'Neutropenia during frontline treatment of advanced Hodgkin lymphoma: Incidence, risk factors, and management', *Critical Reviews in Oncology/Hematology*. Elsevier, 138(March), pp. 1–5. doi: 10.1016/j.critrevonc.2019.03.016.
- Suttitossatam, I. *et al.* (2020) 'Predictors of severe adverse outcomes in febrile neutropenia of pediatric oncology patients at a single institute in Thailand', *Pediatric Hematology and Oncology*. Taylor & Francis, 37(7), pp. 561–572. doi: 10.1080/08880018.2020.1767243.
- Tapia, L. I. *et al.* (2021) 'Cytokine and chemokine profiles in episodes of persistent high-risk febrile neutropenia in children with cancer', *Cytokine*, 148(June). doi:

- 10.1016/j.cyto.2021.155619.
- Triarico, S. *et al.* (2019) 'Impact of malnutrition on survival and infections among pediatric patients with cancer: A retrospective study', *European Review for Medical and Pharmacological Sciences*, 23(3), pp. 1165–1175. doi: 10.26355/eurrev_201902_17010.
- Ulldemolins, M. *et al.* (2011) 'The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients', *Clinical Pharmacokinetics*, 50(2), pp. 99–110. doi: 10.2165/11539220-000000000-00000.
- Unger, S. A., Mark, H. and Pagliari, C. (2019) 'Nutrition: The missing link in the battle against microbial resistance?', *Journal of Global Health*, 9(1), pp. 9–12. doi: 10.7189/jogh.09.010321.
- Verrest, L. *et al.* (2021) 'Influence of Malnutrition on the Pharmacokinetics of Drugs Used in the Treatment of Poverty-Related Diseases: A Systematic Review', *Clinical Pharmacokinetics*. Springer International Publishing, 60(9), pp. 1149–1169. doi: 10.1007/s40262-021-01031-z.
- Voulgaridou, A. *et al.* (2020) 'Pulmonary Infectious Complications in Children with Hematologic Malignancies and Chemotherapy-Induced Neutropenia', *Diseases*, 8(3), p. 32. doi: 10.3390/diseases8030032.
- Wiedermann, C. J. (2021) 'Hypoalbuminemia as surrogate and culprit of infections', *International Journal of Molecular Sciences*, 22(9). doi: 10.3390/ijms22094496.
- Willmer, D. *et al.* (2021) 'Infectious Morbidity in Pediatric Patients Receiving Neoadjuvant Chemotherapy for Sarcoma', pp. 1–13.
- Windiyastuti, E. and Handryastuti, S. (2014) 'Etiologi Demam Neutropenia pada Anak dengan .HJDQDVDQ GDQ 3HQJJXQDDQ 6NRU .ODVLÀNDVL Rondinelli', 16(4), pp. 229–235.
- Yang, C., Li, C. and Wang, S. (2020) 'Clinical strategies for treating pediatric cancer during the outbreak of 2019 novel coronavirus infection', *Pediatric Blood and Cancer*, 67(5), pp. 1–2. doi: 10.1002/pbc.28248.